Prenetics Global Reports Q1 Revenue of $36M, Operating Loss of $8.9M
PRE has more than doubled off its 52-week low of $5.1.
Summary
Prenetics Global reported first-quarter revenue of $36 million, alongside an operating loss of $8.9 million and negative adjusted EBITDA of $5.6 million, with a gross margin of 64%. This financial update provides a critical look at the company's performance following its recent strategic pivot towards consumer health and the growth of its IM8 brand, as detailed in earlier SEC filings. While revenue is reported, the continued operating losses indicate ongoing challenges to profitability. Traders will closely monitor future quarters for signs of improved financial efficiency and the positive impact of its strategic initiatives and partnerships.
At the time of this announcement, PRE was trading at $17.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $295.7M. The 52-week trading range was $5.10 to $23.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.